Cargando…

Low plateletcrit is associated with reduced progression: Free and overall survival in chronic lymphocytic leukemia

BACKGROUND: Alterations of plateletcrit and mean platelet volume (MPV) and pathogenesis of chronic lymphocytic leukaemia (CLL) have been linked to various inflammatory disorders. The prognostic impact of plateletcrit and MPV were evaluated. METHODS: MPV and plateletcrit levels of both CLL and contro...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozbalci, Demircan, Alanoglu, Emine Guchan, Findos, Eda, Eroglu, Hande Nur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Medical Biochemists of Serbia, Belgrade 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040192/
https://www.ncbi.nlm.nih.gov/pubmed/36987410
http://dx.doi.org/10.5937/jomb0-39375
_version_ 1784912428760301568
author Ozbalci, Demircan
Alanoglu, Emine Guchan
Findos, Eda
Eroglu, Hande Nur
author_facet Ozbalci, Demircan
Alanoglu, Emine Guchan
Findos, Eda
Eroglu, Hande Nur
author_sort Ozbalci, Demircan
collection PubMed
description BACKGROUND: Alterations of plateletcrit and mean platelet volume (MPV) and pathogenesis of chronic lymphocytic leukaemia (CLL) have been linked to various inflammatory disorders. The prognostic impact of plateletcrit and MPV were evaluated. METHODS: MPV and plateletcrit levels of both CLL and control group were compared and then in CLL patients, additional diseases, leukocyte count, platelet count, lactate dehydrogenase, Rai stage, progression-free and overall survival, mutations, if any, and chemotherapy, if any, were recorded. Then, the relationship between MPV and plateletcrit values and these parameters were evaluated in CLL patients. RESULTS: Platelet and plateletcrit values were found to be significantly lower in CLL patients than the control group (p<0.001) for both. Plateletcrit and MPV values of patients who did not receive chemotherapy were higher than those who received chemotherapy (p=0.03, p=0.02, respectively). Being over 75 years old, plateletcrit value less than 0.1565 %, platelet level below 175 x 109/L, and leukocyte count greater than 53.5 x 109/L was found to significantly reduce overall survival. Male gender, each stage increase, plateletcrit less than 0.1565 % and leukocyte count greater than 53.5 x 109/L was related to reduce treatment-free survival in CLL patients. CONCLUSIONS: Plateletcrit can be a viable prognostic marker for defining both treatment free and overall survival.
format Online
Article
Text
id pubmed-10040192
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Society of Medical Biochemists of Serbia, Belgrade
record_format MEDLINE/PubMed
spelling pubmed-100401922023-03-27 Low plateletcrit is associated with reduced progression: Free and overall survival in chronic lymphocytic leukemia Ozbalci, Demircan Alanoglu, Emine Guchan Findos, Eda Eroglu, Hande Nur J Med Biochem Original Paper BACKGROUND: Alterations of plateletcrit and mean platelet volume (MPV) and pathogenesis of chronic lymphocytic leukaemia (CLL) have been linked to various inflammatory disorders. The prognostic impact of plateletcrit and MPV were evaluated. METHODS: MPV and plateletcrit levels of both CLL and control group were compared and then in CLL patients, additional diseases, leukocyte count, platelet count, lactate dehydrogenase, Rai stage, progression-free and overall survival, mutations, if any, and chemotherapy, if any, were recorded. Then, the relationship between MPV and plateletcrit values and these parameters were evaluated in CLL patients. RESULTS: Platelet and plateletcrit values were found to be significantly lower in CLL patients than the control group (p<0.001) for both. Plateletcrit and MPV values of patients who did not receive chemotherapy were higher than those who received chemotherapy (p=0.03, p=0.02, respectively). Being over 75 years old, plateletcrit value less than 0.1565 %, platelet level below 175 x 109/L, and leukocyte count greater than 53.5 x 109/L was found to significantly reduce overall survival. Male gender, each stage increase, plateletcrit less than 0.1565 % and leukocyte count greater than 53.5 x 109/L was related to reduce treatment-free survival in CLL patients. CONCLUSIONS: Plateletcrit can be a viable prognostic marker for defining both treatment free and overall survival. Society of Medical Biochemists of Serbia, Belgrade 2023-03-15 2023-03-15 /pmc/articles/PMC10040192/ /pubmed/36987410 http://dx.doi.org/10.5937/jomb0-39375 Text en 2023 Demircan Ozbalci, Emine Guchan Alanoglu, Eda Findos, Hande Nur Eroglu, published by CEON/CEES https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 License.
spellingShingle Original Paper
Ozbalci, Demircan
Alanoglu, Emine Guchan
Findos, Eda
Eroglu, Hande Nur
Low plateletcrit is associated with reduced progression: Free and overall survival in chronic lymphocytic leukemia
title Low plateletcrit is associated with reduced progression: Free and overall survival in chronic lymphocytic leukemia
title_full Low plateletcrit is associated with reduced progression: Free and overall survival in chronic lymphocytic leukemia
title_fullStr Low plateletcrit is associated with reduced progression: Free and overall survival in chronic lymphocytic leukemia
title_full_unstemmed Low plateletcrit is associated with reduced progression: Free and overall survival in chronic lymphocytic leukemia
title_short Low plateletcrit is associated with reduced progression: Free and overall survival in chronic lymphocytic leukemia
title_sort low plateletcrit is associated with reduced progression: free and overall survival in chronic lymphocytic leukemia
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040192/
https://www.ncbi.nlm.nih.gov/pubmed/36987410
http://dx.doi.org/10.5937/jomb0-39375
work_keys_str_mv AT ozbalcidemircan lowplateletcritisassociatedwithreducedprogressionfreeandoverallsurvivalinchroniclymphocyticleukemia
AT alanogluemineguchan lowplateletcritisassociatedwithreducedprogressionfreeandoverallsurvivalinchroniclymphocyticleukemia
AT findoseda lowplateletcritisassociatedwithreducedprogressionfreeandoverallsurvivalinchroniclymphocyticleukemia
AT erogluhandenur lowplateletcritisassociatedwithreducedprogressionfreeandoverallsurvivalinchroniclymphocyticleukemia